Want to see SLGL full AI Analyst Report?
SLGL Stock Chart & Stats
$73.87
-$0.16(-11.43%)
At close: 4:00 PM EST
$73.87
-$0.16(-11.43%)
Day’s Range― - ―
52-Week Range$6.96 - $97.97
Previous CloseN/A
Volume503.92K
Average Volume (3M)16.66K
Market Cap
$242.30M
Enterprise Value$188.43M
Total Cash (Recent Filing)$30.47M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Jul 30, 2026EPS Estimate
-2.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding3,268,991
10 Day Avg. Volume26,975
30 Day Avg. Volume16,656
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)5.15
Price to Sales (P/S)6.06
P/FCF Ratio426.90
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue28.73
Enterprise Value/Gross Profit-18.72
Enterprise Value/Ebitda-11.47
Forecast
1Y Price Target
$234.50Price Target Upside217.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-8.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetVery low absolute debt and historically low leverage give Sol‑Gel durable financial flexibility to fund R&D and commercialization without heavy interest burdens. This reduces near-term insolvency risk and supports strategic optionality while the company pursues its dermatology pipeline.
Revenue Rebound With Strong Product-level EconomicsA sharp revenue rebound and near‑100% gross margin in 2025 indicate strong product economics and improved commercial traction. If sustained, this supports durable unit economics, long‑term gross margin stability, and a path to operating leverage as fixed commercial costs are spread over higher sales.
Successful $33.1M Oversubscribed Equity Offering To Fund SGT‑610An oversubscribed $33.1M raise earmarked for Phase 3 SGT‑610 materially extends runway and funds a pivotal program. Backing from institutional healthcare funds strengthens credibility, reduces immediate financing pressure, and increases the chances of reaching pivotal clinical and commercial inflection points.
Bears Say
Cumulative Equity Erosion From Sustained LossesA materially smaller equity base over several years reduces the company’s capital buffer and financial resilience. Continued erosion limits borrowing capacity, increases vulnerability to adverse shocks, and raises the probability of dilutive financings if profitability and cash generation are not reliably restored.
Persisting Operating Losses And Volatile MarginsOngoing net and EBIT losses, coupled with prior episodes of negative gross profit, show earnings instability. This undermines consistency of cash generation and makes long‑term planning and reinvestment riskier until margins and operating profitability demonstrate sustained improvement.
Historic Cash Burn Creates Funding Risk If Improvement LapsesThe 2025 cash‑flow improvement is encouraging but small relative to prior multi‑year burn. If positive operating/free cash flow isn’t sustained, the company faces renewed financing needs that could dilute shareholders or constrain R&D/commercial investment, threatening long‑term growth prospects.
Sol-Gel Technologies News
SLGL FAQ
What was Sol-Gel Technologies’s price range in the past 12 months?
Sol-Gel Technologies lowest stock price was $6.96 and its highest was $97.97 in the past 12 months.
What is Sol-Gel Technologies’s market cap?
Sol-Gel Technologies’s market cap is $242.30M.
When is Sol-Gel Technologies’s upcoming earnings report date?
Sol-Gel Technologies’s upcoming earnings report date is Jul 30, 2026 which is in 21 days.
How were Sol-Gel Technologies’s earnings last quarter?
Sol-Gel Technologies released its earnings results on May 08, 2026. The company reported $1.31 earnings per share for the quarter, beating the consensus estimate of -$2.86 by $4.17.
Is Sol-Gel Technologies overvalued?
According to Wall Street analysts Sol-Gel Technologies’s price is currently Undervalued.
Does Sol-Gel Technologies pay dividends?
Sol-Gel Technologies does not currently pay dividends.
What is Sol-Gel Technologies’s EPS estimate?
Sol-Gel Technologies’s EPS estimate is -2.9.
How many shares outstanding does Sol-Gel Technologies have?
Sol-Gel Technologies has 3,268,991 shares outstanding.
What happened to Sol-Gel Technologies’s price movement after its last earnings report?
Sol-Gel Technologies reported an EPS of $1.31 in its last earnings report, beating expectations of -$2.86. Following the earnings report the stock price went up 1.898%.
Which hedge fund is a major shareholder of Sol-Gel Technologies?
Currently, no hedge funds are holding shares in SLGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sol-Gel Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$234.50 (217.45% Upside)
$234.50 (217.45% Upside)
Insider Transactions
Bought Shares
Worth $455.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 4.2%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
682.16%
12-Months-Change
Fundamentals
Return on Equity
-3.17%
Trailing 12-Months
Asset Growth
116.35%
Trailing 12-Months
Company Description
Sol-Gel Technologies
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
SLGL Stock 12 Month Forecast
Average Price Target
$234.50
▲(217.45% Upside)
Technical Analysis
Insight Molecular Diagnostics
―
Ovid Therapeutics
―
Shattuck Labs
―
Surrozen
―
Metagenomi, Inc.
―
Ownership Overview
15.50% Insiders
0.04% Mutual Funds
36.17% Other Institutional Investors
48.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---